J Vet Sci.  2007 Mar;8(1):21-25. 10.4142/jvs.2007.8.1.21.

Disposition kinetics and urinary excretion of cefpirome after intravenous injection in buffalo calves

• Rajput N
• Dumka VK
• Sandhu HS

• KMID: 1104232
• DOI: http://doi.org/10.4142/jvs.2007.8.1.21

Abstract

We investigated the disposition kinetics and urinary excretion of cefpirome in buffalo calves after a single intravenous administration of 10 mg/kg. Also, an appropriate dosage regimen was calculated. At 1 min after injection, the concentration of cefpirome in the plasma was 57.4 +/- 0.72 microgram/ml, which declined to 0.22 +/- 0.01 microgram/ml at 24 h. The cefpirome was rapidly distributed from the blood to the tissue compartment as shown by the high distribution coefficient values (8.67 +/- 0.46/h), and by the drug's rate of transfer constant from the central to the peripheral compartment, K12 (4.94 +/- 0.31/h). The elimination halflife and the volume of distribution were 2.14 +/- 0.02 h and 0.42 +/- 0.005 l/kg, respectively. Once the distribution equilibrium was reached between the tissues and plasma, the total body clearance (ClB) and the ratio of the drug present in the peripheral to the central compartment (T/P ratio) were 0.14 +/- 0.002 l/kg/h and 1.73 +/- 0.06, respectively. Based on the pharmacokinetic parameters we obtained, an appropriate intravenous cefpirome dosage regimen for treating cefpiromesensitive bacteria in buffalo calves would be 8.0 mg/kg repeated at 12 h intervals for 5 days, or until persistence of the bacterial infection occurred.

Keyword

buffalo; cefpirome; cephalosporins; dosage; pharmacokinetics

MeSH Terms

Animals
Buffaloes/*metabolism/urine
Cephalosporins/administration & dosage/*pharmacokinetics/*urine
Injections, Intravenous/veterinary
Kinetics
Metabolic Clearance Rate/physiology

Figure

• 

  Fig. 1 Semilogarithmic plot of the plasma concentration-time profile of cefpirome in buffalo calves following a single intravenous dose of 10 mg/kg body weight. Values given are mean ± SE of 5 animals. The data were analyzed using a two-compartment open model. Distribution (α) and elimination (β) phases are represented by least-square regression lines. The calculated points (o) of the distribution phase were obtained by the feathering off technique.

Reference

1. Arai S, Kobayashi S, Hayashi S, Sakaguchi T. Distribution of cefpirome (HR 810) to exudate in the croton oil-induced rat granuloma pouch and its therapeutic effects on experimental infections in the pouch. Antimicrob Agents Chemother. 1988. 32:1396–1399.

2. Arret B, Johnson DP, Kirshbaum A. Outline of details for microbiological assays of antibiotics: second revision. J Pharm Sci. 1971. 60:1689–1694.

3. Bertram MA, Bruckner DA, Young LS. In vitro activity of HR 810, a new cephalosporin. Antimicrob Agents Chemother. 1984. 26:277–279.

4. Dardi MS, Sharma SK, Srivastava AK. Pharmacokinetics and dosage regimen of ceftriaxone in buffalo calves. Vet Res Commun. 2004. 28:331–338.

5. Gardner SY, Papich MG. Comparison of cefepime pharmacokinetics in neonatal foals and adult dogs. J Vet Pharmacol Ther. 2001. 24:187–192.

6. Gibaldi M, Perrier D. Pharmacokinetics. 1982. 2nd ed. New York: Marcel Dekker;433–444.

7. Hancock RE, Bellido F. Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins. J Antimicrob Chemother. 1992. 29:Suppl A. 1–6.

8. Isert D, Klesel N, Limbert M, Markus A, Seibert G, Schrinner E. Pharmacokinetics of cefpirome administered intravenously or intramuscularly to rats and dogs. J Antimicrob Chemother. 1992. 29:Suppl A. 31–37.

9. Jafari HS, Saez-Llorens X, Ramilo O, Shelton SL, McCracken GH Jr. Pharmacokinetics and antibacterial efficacy of cefpirome (HR 810) in experimental Escherichia coli and Haemophilus influenzae type b meningitis. Antimicrob Agents Chemother. 1991. 35:220–223.

10. Kavi J, Ashby JP, Wise R, Donovan IA. Intraperitoneal penetration of cefpirome. Eur J Clin Microbiol Infect Dis. 1989. 8:556–558.

11. Kita Y, Yamaaki T, Imada A. Comparative pharmacokinetics of SCE-2787 and related antibiotics in experimental animals. Antimicrob Agents Chemother. 1992. 36:2481–2486.

12. Klesel N, Seeger K. Pharmacokinetic properties of the new cephalosporin antibiotic HR 810 in animals. Infection. 1983. 11:318–321.

13. Mrestani Y, Bretschneider B, Hartl A, Neubert RHH. In-vitro and in-vivo studies of cefpirom using bile salts as absorption enhancers. J Pharm Pharmacol. 2003. 55:1601–1606.

14. Muller M, Rohde B, Kovar A, Georgopoulos A, Eichler HG, Derendorf H. Relationship between serum and free interstitial concentrations of cefodizime and cefpirome in muscle and subcutaneous adipose tissue of healthy volunteers measured by microdialysis. J Clin Pharmacol. 1997. 37:1108–1113.

15. Nakanomyo H, Esumi Y, Takaichi M, Seki H, Ninomiya S, Okamura Y, Sudo Y. Study on the pharmacokinetics of cefepime (II). Jap J Antibiot. 1992. 45:938–942.

16. Paradis D, Vallee F, Allard S, Bisson C, Daviau N, Drapeau C, Auger F, LeBel M. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem and ciprofloxacin. Antimicrob Agents Chemother. 1992. 36:2085–2092.

17. Rule R, Quiroga GH, Rubio M, Buschiazzo HO, Buschiazzo PM. The pharmacokinetics of ceftazidime in lactating and non-lactating cows. Vet Res Commun. 1996. 20:543–550.

18. Sauermann R, Delle-Karth G, Marsik C, Steiner I, Zeitlinger M, Mayer-Helm BX, Georgopoulos A, Muller M, Joukhadar C. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. Antimicrob Agents Chemother. 2005. 49:650–655.

19. Sharma SK, Srivastava AK. Cefotaxime pharmacokinetics in male buffalo calves following multiple dosing. Vet Arh. 2003. 73:191–197.

20. Wisemann LR, Lamb HM. Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia. Drugs. 1997. 54:117–140.